Recent articles
Here's Why NanoString Technologies Stock Soared 104.7% in the First Half of 2019
Investors are excited (perhaps a little too excited) about a new opportunity in immuno-oncology.
Here's Why NeoGenomics Stock Rose 74% in the First Half of the Year
The genetic testing leader continues to set new quarterly revenue records.
Here's Why Catalent Stock Soared 73.9% in the First Half of 2019
Gene therapies, here we come.
Here's Why BeiGene Lost 11.6% in the First Half of 2019
China's biopharma gem drifted lower in the first half of 2019, but there's no identifiable explanation or cause for concern.
Here's Why U.S. Concrete Shares Gained 40.8% in the First Half of 2019
Wall Street admitted that it may have overreacted last year.
Here's Why Ecolab Rose 34% in the First Half of 2019
Investors were all too happy to reward the business for its hasty progress on an operating efficiency program.
Here's Why Repligen Gained 62.9% in the First Half of 2019
The bioprocess engineering leader continued to deliver spectacular growth and bolster its profitability.
3 Stocks to Hold for the Next 20 Years
These businesses are likely to be better than ever two decades from now.
Here's Why Amneal Pharmaceuticals Fell as Much as 36.6% Today
Stubborn headwinds in the generic-drug markets are forcing the company to restructure operations.
Here's Why CRISPR Gene Editing Stocks Rose as Much as 32.4% in June
The field expanded into a new therapeutic area, and fell back into a bitter dispute over intellectual property.
Here's Why Moderna Lost 29.6% in June
The post-IPO blues hit pretty hard last month.
Here's Why Galapagos NV Stock Rose 13.4% in June
The good news keeps rolling in for this Belgian pharma.
Here's Why Nektar Therapeutics Stock Gained 13.6% in June
Was last month a turning point in a not-so-good year for shareholders?
Here's Why Zogenix Shares Leaped 26.8% in June
The company rebounded after remedying an embarrassing regulatory gaffe.
Why Iovance Biotherapeutics Stock Soared 50% in June
The clinical-stage biopharma announced promising data at a major conference.
Here's Why ArQule Jumped 53.1% in June
The pharmaceutical pipeline shined, and the business doubled its cash position.
Here's Why Coherus BioSciences Is Falling Today
The business reported an upbeat update, but something got lost in translation on Wall Street.
Are Natural Killer Cells the Next Big Thing in Immunotherapy?
The immune cells live up to their name in natural settings, but engineered therapies have delivered mixed results in clinical trials.
2 Companies Building the Circular Economy
These businesses are turning wasteful consumption into long-term value for shareholders and the planet.
3 Top Stocks That Aren't On Wall Street's Radar
Wall Street might be overlooking these intriguing investing opportunities.